Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 27

1.

Interleukin-6 trans-signaling contributes to chronic hypoxia-induced pulmonary hypertension.

Maston LD, Jones DT, Giermakowska W, Resta TC, Ramiro-Diaz J, Howard TA, Jernigan NL, Herbert L, Maurice AA, Gonzalez Bosc LV.

Pulm Circ. 2018 Jul-Sep;8(3):2045894018780734. doi: 10.1177/2045894018780734. Epub 2018 May 16.

2.

Integrin linked kinase regulates the transcription of AQP2 by NFATC3.

Hatem-Vaquero M, Griera M, Giermakowska W, Luengo A, Calleros L, Gonzalez Bosc LV, Rodríguez-Puyol D, Rodríguez-Puyol M, De Frutos S.

Biochim Biophys Acta Gene Regul Mech. 2017 Sep;1860(9):922-935. doi: 10.1016/j.bbagrm.2017.07.006. Epub 2017 Jul 20.

PMID:
28736155
3.

Central role of T helper 17 cells in chronic hypoxia-induced pulmonary hypertension.

Maston LD, Jones DT, Giermakowska W, Howard TA, Cannon JL, Wang W, Wei Y, Xuan W, Resta TC, Gonzalez Bosc LV.

Am J Physiol Lung Cell Mol Physiol. 2017 May 1;312(5):L609-L624. doi: 10.1152/ajplung.00531.2016. Epub 2017 Feb 17.

4.

NFAT regulation of cystathionine γ-lyase expression in endothelial cells is impaired in rats exposed to intermittent hypoxia.

Gonzalez Bosc LV, Osmond JM, Giermakowska WK, Pace CE, Riggs JL, Jackson-Weaver O, Kanagy NL.

Am J Physiol Heart Circ Physiol. 2017 Apr 1;312(4):H791-H799. doi: 10.1152/ajpheart.00952.2015. Epub 2017 Jan 27.

5.

NFATc3 and VIP in Idiopathic Pulmonary Fibrosis and Chronic Obstructive Pulmonary Disease.

Szema AM, Forsyth E, Ying B, Hamidi SA, Chen JJ, Hwang S, Li JC, Sabatini Dwyer D, Ramiro-Diaz JM, Giermakowska W, Gonzalez Bosc LV.

PLoS One. 2017 Jan 26;12(1):e0170606. doi: 10.1371/journal.pone.0170606. eCollection 2017.

6.

ASIC1-mediated calcium entry stimulates NFATc3 nuclear translocation via PICK1 coupling in pulmonary arterial smooth muscle cells.

Gonzalez Bosc LV, Plomaritas DR, Herbert LM, Giermakowska W, Browning C, Jernigan NL.

Am J Physiol Lung Cell Mol Physiol. 2016 Jul 1;311(1):L48-58. doi: 10.1152/ajplung.00040.2016. Epub 2016 May 17.

7.

Mechanisms of NFATc3 activation by increased superoxide and reduced hydrogen peroxide in pulmonary arterial smooth muscle.

Ramiro-Diaz JM, Giermakowska W, Weaver JM, Jernigan NL, Gonzalez Bosc LV.

Am J Physiol Cell Physiol. 2014 Nov 15;307(10):C928-38. doi: 10.1152/ajpcell.00244.2014. Epub 2014 Aug 27.

8.

Intermittent hypoxia-induced increases in reactive oxygen species activate NFATc3 increasing endothelin-1 vasoconstrictor reactivity.

Friedman JK, Nitta CH, Henderson KM, Codianni SJ, Sanchez L, Ramiro-Diaz JM, Howard TA, Giermakowska W, Kanagy NL, Gonzalez Bosc LV.

Vascul Pharmacol. 2014 Jan;60(1):17-24. doi: 10.1016/j.vph.2013.11.001. Epub 2013 Nov 15.

9.

NFAT is required for spontaneous pulmonary hypertension in superoxide dismutase 1 knockout mice.

Ramiro-Diaz JM, Nitta CH, Maston LD, Codianni S, Giermakowska W, Resta TC, Gonzalez Bosc LV.

Am J Physiol Lung Cell Mol Physiol. 2013 May 1;304(9):L613-25. doi: 10.1152/ajplung.00408.2012. Epub 2013 Mar 8.

10.

HIV-specific immunity during structured antiviral drug treatment interruption.

Moss RB, Brandt C, Giermakowska WK, Savary JR, Theofan G, Zanetti M, Carlo DJ, Wallace MR.

Vaccine. 2003 Mar 7;21(11-12):1066-71.

PMID:
12559781
11.

Predictors of HIV-specific lymphocyte proliferative immune responses induced by therapeutic vaccination.

Moss RB, Wallace MR, Steigbigel RT, Morrison SA, Giermakowska WK, Nardo CJ, Diveley JP, Carlo DJ.

Clin Exp Immunol. 2002 May;128(2):359-64.

12.

Expression of perforin on HIV-1-specific CD8+ lymphocytes after immunization with a gp120-depleted, whole-killed HIV-1 immunogen.

Moss RB, Giermakowska WK, Wallace MR, Jensen FC, Maigetter RZ, Carlo DJ.

Clin Exp Immunol. 2001 May;124(2):248-54.

14.
15.

CXCR4 and CCR5 expression on CD4+ T cells in vivo and HIV-1 antigen beta-chemokine production in vitro after treatment with HIV-1 immunogen (REMUNE).

Moss RB, Giermakowska WK, Diveley JP, Savary JR, Wallace MR, Maigetter RZ, Jensen FC, Carlo DJ.

J Hum Virol. 2000 Jan-Feb;3(1):44-9.

PMID:
10774806
16.

Cell-mediated immune responses to autologous virus in HIV-1-seropositive individuals after treatment with an HIV-1 immunogen.

Moss RB, Giermakowska WK, Wallace MR, Savary JR, Jensen FC, Carlo DJ.

AIDS. 2000 Nov 10;14(16):2475-8.

PMID:
11101057
17.

Phenotypic analysis of human immunodeficiency virus (HIV) type 1 cell-mediated immune responses after treatment with an HIV-1 immunogen.

Moss RB, Wallace MR, Giermakowska WK, Webb E, Savary J, Chamberlin-Brandt C, Theofan G, Musil R, Richieri SP, Jensen FC, Carlo DJ.

J Infect Dis. 1999 Sep;180(3):641-8.

PMID:
10438350
18.

Tumor necrosis factor alpha and human immunodeficiency virus-specific functional immune responses after immunization with Gp120-depleted, inactivated HIV-1 in incomplete Freund's adjuvant (REMUNE) in HIV-1-seropositive subjects.

Moss RB, Li L, Giermakowska WK, Lanza P, Turner JL, Wallace MR, Jensen FC, Richieri SP, Daigle AE, Theofan G, Carlo DJ.

J Hum Virol. 1998 Jan-Feb;1(2):77-81.

PMID:
10195235
19.

A primer on HIV type 1-specific immune function and REMUNE.

Moss RB, Giermakowska WK, Savary JR, Theofan G, Daigle AE, Richieri SP, Jensen FC, Carlo DJ.

AIDS Res Hum Retroviruses. 1998 Jun;14 Suppl 2:S167-75. Review.

PMID:
9672235
20.
21.

Whole-killed gp120-depleted HIV-1 antigen in a murine model for prophylactic vaccination.

Lanza P, Moss RB, Giermakowska W, Hancock RB, Richieri SP, Theofa G, Jensen FC, Salk PL, Carlo DJ.

Vaccine. 1998 Apr;16(7):727-31.

PMID:
9562693
22.

HIV-1-Specific Functional Immune Measurements as Markers of Disease Progression.

Moss RB, Richieri SP, Ferre F, Daigle AE, Trauger R, Theofan G, Giermakowska W, Lanza P, Brostoff S, Carlo DJ, Jensen FC.

J Biomed Sci. 1997 Jul-Aug;4(4):127-131.

PMID:
11725144
23.

Effect of immunization with an inactivated gp120-depleted HIV-1 immunogen on beta-chemokine and cytokine production in subjects with HIV-1 infection.

Moss RB, Trauger RJ, Giermakowska WK, Turner JL, Wallace MR, Jensen FC, Richieri SP, Ferre F, Daigle AE, Duffy C, Theofan G, Carlo DJ.

J Acquir Immune Defic Syndr Hum Retrovirol. 1997 Apr 1;14(4):343-50.

PMID:
9111476
25.

Autoproliferation in HIV-1-infected patients undergoing active HIV-1-specific immunotherapy.

Trauger RJ, Giermakowska W, Wormsley S, Turner J, Jensen FC, Carlo DJ.

Clin Exp Immunol. 1995 Apr;100(1):7-12.

26.

Safety and immunogenicity of a gp120-depleted, inactivated HIV-1 immunogen: results of a double-blind, adjuvant controlled trial.

Trauger RJ, Daigle AE, Giermakowska W, Moss RB, Jensen F, Carlo DJ.

J Acquir Immune Defic Syndr Hum Retrovirol. 1995;10 Suppl 2:S74-82.

PMID:
7552517
27.

Cell-mediated immunity to HIV-1 in Walter Reed stages 1-6 individuals: correlation with virus burden.

Trauger RJ, Giermakowska WK, Ferre F, Duffy PC, Wallace MR, Lewis DE, Beecham HJ, Burnett KG, Jensen FC, Carlo DJ.

Immunology. 1993 Apr;78(4):611-5.

Supplemental Content

Loading ...
Support Center